Controllo lipidico in pazienti ad elevato rischio cardiovascolare: Focus sull'inibizione di PCSK9

Translated title of the contribution: Lipid control in high cardiovascular risk patients: Focus on PCSK9 inhibition

Pasquale Perrone Filardi, Stefania Paolillo, Bruno Trimarco

Research output: Contribution to journalArticlepeer-review


Low-density lipoprotein (LDL)-cholesterol levels are strictly related to the risk of major cardiovascular events. Statins have been demonstrated to significantly reduce LDL-cholesterol levels, contributing to cardiovascular risk reduction especially in high-risk patients. However, low adherence to statins, due to adverse effects, is often observed and many patients in secondary prevention exhibit LDL-cholesterol levels >70 mg/dl. As a consequence, there is the need for new therapeutic approaches with different mechanisms of action to reach recommended lipid targets in high-risk patients. One potential approach is to inhibit PCSK9, a serum protein with an active role in controlling the expression of LDL receptors, by reducing their recycling and targeting it for lysosomal destruction. Monoclonal antibodies against PCSK9, in particular alirocumab and evolocumab, have been shown to reduce LDL substantially, either with or without concomitant statin therapy with good tolerability. Ongoing trials will further define the efficacy of these drugs as an emerging approach to the treatment of hypercholesterolemia in primary and secondary prevention of high-risk patients.

Translated title of the contributionLipid control in high cardiovascular risk patients: Focus on PCSK9 inhibition
Original languageItalian
Pages (from-to)44-51
Number of pages8
JournalGiornale Italiano di Cardiologia
Issue number1
Publication statusPublished - Jan 1 2015

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Medicine(all)


Dive into the research topics of 'Lipid control in high cardiovascular risk patients: Focus on PCSK9 inhibition'. Together they form a unique fingerprint.

Cite this